Zymeworks and XOMA (US) LLC (XOMA) to Collaborate on Antibody Research Program  
5/15/2009 11:07:03 AM

VANCOUVER--(BUSINESS WIRE)--Zymeworks Inc., a privately held computational biotechnology company, today announced it has entered into a research agreement with California-based XOMA Ltd. (Nasdaq: XOMA, to optimize an undisclosed antibody using Zymeworks’ ZymeCAD™ suite of predictive protein engineering tools and XOMA’s innovative Targeted Affinity Enhancement™ (TAE™) technology for antibody mutagenesis and optimization. Financial terms are not disclosed.